Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg

Clinical Pharmacokinetics

Volumn 37, Issue SUPPL. 1, 1999, Pages 13-19

  Damien, Gérard ^a   Huet De Barochez, Bruno ^a   Schiavi, Pierre ^a,b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLYCEROL; HYDROXYPROPYLMETHYLCELLULOSE; INDAPAMIDE; LACTOSE; MACROGOL 6000; MAGNESIUM STEARATE; POVIDONE; SILICON DIOXIDE; TITANIUM DIOXIDE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG TOLERABILITY; HUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET;

EID: 0345192298     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937001-00003     Document Type: Review

References (16)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med 1997; 157 (21): 2413-46
2. 1999 World Health Organisation. International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83
3. Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide; results of randomised double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677-84
4. Mallion JM, Asmar R, Routelant S, et al. Twenty-four hour antihypertensive efficacy of indapamide 1.5 mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32: 673-8
5. Hui HW, Robinson JR, Lee VHL. Design and fabrication of oral controlled release drug delivery systems. In: Robinson JR, Lee VHL, editors. Controlled drug delivery, fundamentals and applications. New York; Marcel Dekker, 1987; 373-432
6. Huet de Baroehez B, Lapeyre F, Cuiné A. Oral sustained release dosage forms. Comparison between matrices and reservoir devices. Drug Dev Ind Pharm 1989; 15: 1001-20
7. Segot-Chicq S, Teillaud E, Peppas NA. Les dispositifs à libération contrôlée pour la délivrance des principes actifs médicamenteux. I. Intérêt et applications, STP Pharma 1985; 1 (1): 25-36
8. Avan JL, Brossard C. Mise au point et développement technologique de matrices hydrophiles par compression directe sur machine rotative. STP Pharma 1985; 1 (6): 516-622
9. Ford JL, Rubinstein MH, McCaul F. Importance of drug type, tablet shape and formulation on release from hydroxypropylmethyl cellulose matrix tablets. Proceedings of the 6th Pharmaceutical Technology Conference; 1987 Apr 7-9; Canterbury, Vol. I: 82-7
10. Catellani L, Vaona G, Plazzi P, et al. Compressed matrices: formulation and drug release kinetics. Acta Pharm Technol 1988; 34 (1): 38-41
11. Peppas NA, Segot-Chicq S. Les dispositifs à libération contrôlée pour la délivrance des principes actifs médicamenteux, III. Modélisation des mécanismes diffusionnels. STP Pharma 1985; 1 (3): 208-16
12. Cuiné A, Huet de Barochez B, Guez D. US Patent No. 5,334,392
13. Gordon B, Ings RMJ. The relative bioavailability of two new controlled release formulations of indapamide. Fulmer Hall, UK: Servier, 1990, Report No.: NP 924
14. Bass S, Falcoz C. Bioequivalence study between two slow release batches of indapamide SR 1.5 mg with different dissolution profiles after repeated oral administration over 7 days in 12 healthy volunteers; a randomised double blind cross over study. Fulmer Hall, UK: Servier, 1993, Report No.: NP 910
15. Schiavi P, Jochemsen R, Hiley M, et al. Pharmacokinetics of slow and immediate release formulations of indapamide after single oral administration under fasting conditions and after food, in healthy volunteers. Eur J Drug Metab Pharmacokinet 1996; Special Issue: 42
16. Schiavi P, Jochemsen R, Gordon B, et al. Pharmacokinetics of slow and immediate release formulations of indapamide after repeated administration, in healthy volunteers. Eur J Drug Metab Pharmacokinet 1996; Special Issue: 41